MDRTB if the infecting bacilli are resistant at least to isoniazid and rifampicin (WHO , 2003 . Since treatment of MDR-TB tends to be more toxic than that of susceptible cases , many MDR-TB patients are initially hospitalized . However , to prevent nosocomial transmission of MDR-TB to other patients as well as to the staff , patients are started on ambulatory treatment as soon as their cooperation and tolerance of the drug regimen have been ensured (WHO , 2003 . The World Health Organization (2003 ) recommends that...
treatment ~
world health organization ~
england ~
infections ~
england journal ~
mrsa ~
resistant ~
petri ~
pbp ~
vrsa
SUBJECTS
